NOV 20, 2017 3:22 PM PST

Scientists Target Prostate Cancer with an Antiparasitic Drug

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

A substance found in an antiparasitic drug could block vital communication for prostate and colon cancer cells, a new study reports.

Prostate cancer represents a huge health risk for half the world’s population, as it is the most common form of cancer in men, second only to skin cancer. The American Cancer Society estimates that over 180,000 new prostate cancer cases will be diagnosed this year.

As for colon cancer, also known as colorectal cancer or bowel cancer, this is the third most common non-skin cancer type in the world. According to a recent report, the incidence of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030.

Both types of cancer share a common signaling pathway known as Wnt (wingless)/Beta-catenin signaling. This cascade of signals help the cancer cells grow and proliferate uncontrollably. Blocking this pathway then could be a way to slow prostate and colon cancer progression, hypothesized the research team from the University of Bergen in Norway.

With that aim in mind, the team began searching for a substance that could block Wnt signaling. They landed on a compound called nitazoxanide (NTZ) that fit the bill perfectly. And results from human colon cancer cells are promising.

"We discovered that this specific substance is blocking the signaling pathway in the cancer cells, and [making] them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one,” said Karl-Henning Kalland, a professor at the University of Bergen, Norway.

"We are the first researchers," he added, "who have mapped the complex molecular mechanisms involved in this process."

It’s worth noting why researchers get more excited when a pre-existing drug shows promise for a new disease. Because so much money and time are spent for every drug that’s on the market, finding new uses for these commercially available drug effectively reduces the burden on the industry and patients could have more options sooner rather than later. With the toxicity and pharmacokinetics of a drug already known, makers can shave off as much as 15 years off the pipeline to get the drug to patients' hands.

"The advantage of testing already-approved drugs," explained Prof. Kalland, "is that we know they work in the human body and have no serious side effects, which means that a future treatment may happen quicker."

But given the limited scope of this initial study, the team is tempering their optimism with caution. "At the moment," said Prof. Kalland, "we are working on how to strengthen our ongoing immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ." If all goes well, they could be the first to spearhead a clinical trial to test NTZ in patients with prostate cancer.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 07, 2020
Cancer
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
OCT 07, 2020
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
Over the years, cancer researchers have struggled not just with drug and diagnostic design, but with drug delivery. The ...
OCT 05, 2020
Cancer
Fighting mitochondrial terminal exhaustion
OCT 05, 2020
Fighting mitochondrial terminal exhaustion
New findings reported in Nature Immunology highlight how the tumor microenvironment attacks the mitochondria of T l ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
OCT 23, 2020
Cancer
#BCSM helps physicians understand patients' needs outside the clinical setting
OCT 23, 2020
#BCSM helps physicians understand patients' needs outside the clinical setting
A new study from UCLA published in the Journal of Patient-Centered Research and Review suggests that social media can be ...
NOV 02, 2020
Cancer
Age impacts response to melanoma treatment
NOV 02, 2020
Age impacts response to melanoma treatment
Research from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Bloomberg School of Public Health& ...
NOV 09, 2020
Cancer
A Prognostic Expression Profile for Osteosarcoma
NOV 09, 2020
A Prognostic Expression Profile for Osteosarcoma
Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps fo ...
Loading Comments...